The stock of Bone Biologics Corp (BBLG) has seen a -25.64% decrease in the past week, with a -57.35% drop in the past month, and a -26.58% decrease in the past quarter. The volatility ratio for the week is 13.04%, and the volatility levels for the past 30 days are at 15.00% for BBLG. The simple moving average for the past 20 days is -27.36% for BBLG’s stock, with a -52.85% simple moving average for the past 200 days.
Is It Worth Investing in Bone Biologics Corp (NASDAQ: BBLG) Right Now?
Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BBLG is 0.51M, and currently, short sellers hold a 3.57% ratio of that float. The average trading volume of BBLG on September 04, 2024 was 2.09M shares.
BBLG) stock’s latest price update
The stock price of Bone Biologics Corp (NASDAQ: BBLG) has dropped by -17.14 compared to previous close of 1.40. Despite this, the company has seen a fall of -25.64% in its stock price over the last five trading days. businesswire.com reported 2024-08-02 that BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 781,251 shares of its common stock having an exercise price of $2.43 per share, originally issued in March 2024. The issuance of the shares of common stock issuable upon exerc.
BBLG Trading at -22.72% from the 50-Day Moving Average
After a stumble in the market that brought BBLG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.02% of loss for the given period.
Volatility was left at 15.00%, however, over the last 30 days, the volatility rate increased by 13.04%, as shares sank -51.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.20% lower at present.
During the last 5 trading sessions, BBLG fell by -25.64%, which changed the moving average for the period of 200-days by -71.00% in comparison to the 20-day moving average, which settled at $1.5365. In addition, Bone Biologics Corp saw -74.34% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BBLG starting from Walsh Deina H, who purchase 8,000 shares at the price of $0.64 back on Sep 13 ’23. After this action, Walsh Deina H now owns 15,000 shares of Bone Biologics Corp, valued at $5,120 using the latest closing price.
Frelick Jeff, the Chief Executive Officer of Bone Biologics Corp, purchase 9,500 shares at $0.69 during a trade that took place back on Sep 11 ’23, which means that Frelick Jeff is holding 17,204 shares at $6,530 based on the most recent closing price.
Stock Fundamentals for BBLG
The total capital return value is set at -1.7. Equity return is now at value -119.03, with -94.66 for asset returns.
Currently, EBITDA for the company is -9.43 million with net debt to EBITDA at 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.22.
Conclusion
To put it simply, Bone Biologics Corp (BBLG) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
